C57BL/6JGpt-Cdh5-P2A-CreERT2

Strain Name： C57BL/6JGpt-*Cdh5*$^{em1Cin(P2A-CreERT2)}$/Gpt
Strain Type： Knock-in
Strain Number： T052686
Background： C57BL/6JGpt

Description

This mouse strain expresses CreERT2 inducible recombinase [1] under the control of the mouse endogenous *Cdh5* promoter, the construct was inserted into the targeted stop codon of the *Cdh5* gene by CRISPR/Cas9 technology. When crossed with a strain with loxP site flanked sequence in its genome, Cre-mediated recombination will result in excision of the DNA fragment between the two loxPs in vascular endothelial cells after tamoxifen administration.

Strategy



Fig.1 Schematic diagram of C57BL/6JGpt-Cdh5-P2A-CreERT2 model strategy.

Applications

1. Cre tool mice for specific, tamoxifen dependent induction of loxP recombination in vascular endothelial cells [2-3].

Data support

1. Validation methods & notes

Cdh5-P2A-CreERT2 mice was crossed with CAG-loxp-ZsGreen-Stop-loxp-tdTomato mice with ubiquitous reporter expression (hereafter referred as CAG-G/R mice), Cre-mediated recombination will lead to excision of ZsGreen and the stop cassette and expression of tdTomato, thus loss of green fluorescence and gain of red fluorescence will indicate Cre activity. Fluorescence imaging of frozen sections were performed to exhibit Cre activity in various tissues and organs. Imaging of sections were performed under a 200x microscopy. For tamoxifen administration, 0.25 mL of 5 mg/mL tamoxifen was treated through intraperitoneal injection daily from P43 to P49 (6.1 w~7.0 w).
Note: these results may only represent the activity of CreERT2 in this strain under this certain tamoxifen treatment condition at the identical stage. Recombinase activity may be different at other stages or under different tamoxifen induction conditions in your application.

2. Timeline of tamoxifen treatment and imaging



Fig 2. Timeline of tamoxifen treatment and experiment analysis of Cdh5-P2A-CreERT2 mice.

3. Images of tissues and organs with obvious Cre activity




Lung
DAPI
ZsGreen
tdTomato
Merge
Tam-
Tam+
Heart
DAPI
ZsGreen
tdTomato
Merge
Tam-
Tam+
Liver
DAPI
ZsGreen
tdTomato
Merge
Tam-
Tam+
Spleen
DAPI
ZsGreen
tdTomato
Merge
Tam-
Tam+



Fig 3. Fluorescence imaging of tissues and organs with obvious Cre activity.
Organ name was indicated in the left top of each subfigure group. Tam-: Cdh5-P2A-CreERT2, CAG-G/R double positive individuals without tamoxifen administration; Tam+: Cdh5-P2A-CreERT2, CAG-G/R double positive individuals with tamoxifen administration.

4. Images of tissues and organs with little or no Cre activity



Fig 4. Fluorescence imaging of tissues and organs with little or no Cre activity.
Organ name was indicated in the left top of each subfigure group. Tam-: Cdh5-P2A-CreERT2, CAG-G/R double positive individuals without tamoxifen administration; Tam+: Cdh5-P2A-CreERT2, CAG-G/R double positive individuals with tamoxifen administration.

Reference

1. Feil R, Wagner J, Metzger D, et al. "Regulation of Cre recombinase activity by mutated estrogen receptor ligand-binding domains." Biochem Biophys Res Commun, 1997, 237(3): 752-757.
2. Gory S, Vernet M, Laurent M, et al. The vascular endothelial-cadherin promoter directs endothelial-specific expression in transgenic mice. Blood, 1999, 93(1): 184-92.
3. Monvoisin A, Alva JA, Hofmann JJ, et al. VE-cadherin-CreERT2 transgenic mouse: a model for inducible recombination in the endothelium. Dev Dyn, 2006, 235(12): 3413-22.